pregabalin with chymotrypsin
Reading File
Pregabalin is an anticonvulsant/neuropathic pain agent, and chymotrypsin is a proteolytic enzyme used as an anti-inflammatory. Their combination is used clinically for post-operative or post-traumatic pain and edema management.
Searching sources...
Finding Sources
Finding Sources
Searching the Web
pregabalin chymotrypsin combination tablet clinical use indications
The web search didn't surface the combination product directly. Let me search more specifically for this fixed-dose combination that is popular in India.
Finding Sources
Searching the Web
pregabalin chymotrypsin fixed dose combination India anti-inflammatory neuropathic pain
Finding Sources
Reading File
Searching the Web
chymotrypsin trypsin serratiopeptidase enzyme tablet anti-inflammatory mechanism post-operative swelling
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC5778189
Searching PubMed
pregabalin chymotrypsin combination neuropathic pain
Now I have enough information to provide a thorough answer on the combination of pregabalin and chymotrypsin.
Pregabalin + Chymotrypsin (Fixed-Dose Combination)
This is a fixed-dose combination (FDC) popular in India and other South Asian markets. The two drugs address different aspects of pain and inflammation, making their combination rational for conditions with both a neuropathic and a tissue-inflammatory component.
Individual Components
Pregabalin
| Property | Detail |
|---|---|
| Class | Gabapentinoid; GABA analog (but does NOT act on GABA receptors) |
| Mechanism | Binds to the α2-δ subunit of voltage-gated calcium channels in dorsal horn neurons → reduces release of excitatory neurotransmitters (glutamate, substance P, norepinephrine) → central pain modulation |
| Pharmacokinetics | Rapid oral absorption, NOT protein bound, minimal hepatic metabolism, ~95% excreted unchanged in urine, t½ ~6 hours; no significant drug-drug interactions via CYP enzymes |
| Indications | Diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury pain, partial-onset seizures, generalized anxiety disorder |
| Dose range | 75-300 mg/day (in 2-3 divided doses) |
| Side effects | Dizziness, sedation, dry mouth, peripheral edema, weight gain |
(Bradley and Daroff's Neurology in Clinical Practice)
Chymotrypsin (Oral Proteolytic Enzyme)
Often combined with trypsin (as trypsin:chymotrypsin) in tablet form.
| Property | Detail |
|---|---|
| Class | Serine protease (proteolytic enzyme) |
| Mechanism | Hydrolyzes proteins and peptides at sites of inflammation and injury → breaks down necrotic tissue and inflammatory exudates → reduces edema and tissue destruction; enhances microcirculation; maintains α1-antitrypsin levels; augments phagocytic activity of NK cells and macrophages; antioxidant and fibrinolytic activity |
| Properties | Anti-inflammatory, anti-edematous, fibrinolytic, antioxidant, analgesic, anti-infective |
| Indications | Post-traumatic/post-surgical swelling and pain, soft tissue injuries, musculoskeletal disorders (tendinitis, bursitis, arthritis), wound healing |
| Dose | 1-2 tablets orally after food, as directed |
| Side effects | GI discomfort; rarely allergic reactions |
(PMC5778189 - Trypsin:Chymotrypsin in Tissue Repair)
Rationale for the Combination
The combination targets pain through two distinct and complementary pathways:
- Pregabalin - addresses the central/neuropathic component: modulates central sensitization, reduces hyperalgesia and allodynia by dampening spinal cord excitatory neurotransmission.
- Chymotrypsin - addresses the peripheral/inflammatory component: reduces local edema, inflammatory exudate, and tissue damage at the injury site, thereby reducing the nociceptive input that drives or sustains pain.
This dual mechanism is why the combination is especially useful in conditions where both nerve sensitization and tissue inflammation coexist.
Clinical Use Cases
- Post-operative pain management - particularly after orthopedic, dental, or spinal surgeries
- Musculoskeletal pain with nerve involvement - e.g., cervical or lumbar disc disease causing radiculopathy plus local soft tissue swelling
- Diabetic peripheral neuropathy with associated tissue inflammation
- Post-traumatic conditions involving both nerve injury and soft tissue damage
- Adjunct in multimodal analgesia to reduce opioid consumption
Pharmacokinetic Interactions
There are no known significant pharmacokinetic interactions between pregabalin and chymotrypsin. Pregabalin lacks hepatic CYP-mediated metabolism, so enzyme induction/inhibition is not a concern. The main caution for chymotrypsin (especially when combined with trypsin) is use alongside anticoagulants (warfarin, aspirin) - the proteolytic/fibrinolytic activity may potentiate bleeding risk.
Common FDC Products (Indian Market)
Brands like Pregastat-C, Chymoral Forte + Pregabalin, and similar combinations pair pregabalin (typically 75 mg) with chymotrypsin (or trypsin-chymotrypsin) to treat neuropathic pain with an inflammatory component. These are primarily marketed as anti-inflammatory + neuropathic pain combinations.
Note: No formal randomized clinical trials were found on PubMed specifically evaluating this pregabalin + chymotrypsin FDC, so clinical evidence for the specific combination is largely pharmacological rationale and observational/marketing data rather than high-quality RCT evidence. Each component individually has good evidence for its own indicated uses.
hydroxychloroquine dose
Hydroxychloroquine (HCQ) dosing depends on the indication. Standard doses: RA/SLE - 200-400 mg/day (max 5 mg/kg/day real body weight to avoid retinal toxicity); malaria treatment - 800 mg loading then 400 mg at 6, 24, 48 hours; malaria prophylaxis - 400 mg weekly.
Searching sources...
Finding Sources
Searching the Web
hydroxychloroquine dosing guidelines 2024 SLE rheumatoid arthritis retinal toxicity
Reading File
Reading File
Reading Web Page
https://conexiant.com/ophthalmology/articles/aao-updates-hcq…
Finding Sources
Finding Sources
Reading File
Finding Sources
Now I have comprehensive data from textbooks and current guidelines. Here is the full answer:
Hydroxychloroquine (HCQ) Dosing
Key safety rule (AAO 2016, reaffirmed 2026): Maximum dose = 5 mg/kg/day of actual (real) body weight to minimize retinal toxicity.
1. Rheumatologic / Autoimmune Indications
Systemic Lupus Erythematosus (SLE)
| Parameter | Detail |
|---|---|
| Dose | 200-400 mg/day orally (once daily or in 2 divided doses) |
| Weight-based cap | ≤ 5 mg/kg/day of actual body weight |
| Duration | Long-term (indefinite); discontinuation risks lupus flare |
| Pregnancy | Continue throughout - reduces flare risk and fetal growth restriction; not teratogenic |
In children: 3.1-5 mg/kg/24 hr (base), once daily or twice daily; max 310 mg/24 hr (Harriet Lane Handbook)
Rheumatoid Arthritis
| Parameter | Detail |
|---|---|
| Dose | 200-400 mg/day (≤ 5 mg/kg/day actual body weight) |
| Role | Part of "triple therapy" (HCQ + sulfasalazine + methotrexate) - as effective as MTX + TNF inhibitor |
Dermatologic Use (Cutaneous Lupus, Dermatomyositis, etc.)
- Usually 200 mg once or twice daily
- In porphyria cutanea tarda: a low-dose regimen (100 mg HCQ twice weekly) is used to avoid precipitation (Fitzpatrick's Dermatology)
2. Malaria
Doses below are expressed as HCQ base (tablets contain 200 mg salt = 155 mg base). Always clarify salt vs. base.
Malaria Prophylaxis (chloroquine-sensitive areas)
| Population | Dose |
|---|---|
| Adults | 310 mg base (= 400 mg salt) PO once weekly |
| Children | 5 mg/kg base PO once weekly; max 310 mg/dose |
- Start 2 weeks before travel to endemic area
- Continue 4 weeks after leaving
Malaria Treatment (acute uncomplicated, chloroquine-sensitive)
| Population | Regimen |
|---|---|
| Adults | 620 mg base (×1) → 310 mg at 6 hr → 310 mg at 24 hr → 310 mg at 48 hr |
| Children | 10 mg/kg base (max 620 mg) ×1 → 5 mg/kg (max 310 mg) at 6 hr → 5 mg/kg at 24 hr and 48 hr |
(Harriet Lane Handbook, 23rd ed.)
3. Retinal Toxicity - Critical Safety Information
HCQ retinopathy is dose- and duration-dependent, causing irreversible macular damage ("bull's eye" maculopathy).
| Risk factor | Threshold |
|---|---|
| Daily dose limit (HCQ) | ≤ 5 mg/kg/day actual body weight |
| Daily dose limit (Chloroquine) | ≤ 2.3 mg/kg/day |
Updated AAO 2026 guidance (AAO April 2026):
- At doses ≤ 5 mg/kg/day: risk < 1% within 5 years, < 2% within 10 years, < 5% even after 20 years
- Risk rises significantly above 5 mg/kg/day
- Preferred screening tools: OCT + fundus autofluorescence (FAF); visual fields and multifocal ERG used for confirmation
- Baseline exam near treatment initiation; annual screening thereafter (may defer up to 5 years if no major risk factors)
(Firestein & Kelley's Textbook of Rheumatology; Goldman-Cecil Medicine)
4. Other Adverse Effects
| Effect | Notes |
|---|---|
| GI disturbance | Take with food |
| Skin/mucosal pigmentation | Blue-gray on lower extremities |
| QT prolongation | ECG monitoring if combined with other QT-prolonging drugs |
| Cardiomyopathy | Rare, long-term |
| Proximal myopathy / peripheral neuropathy | Rare |
| Hypoglycemia | Monitor in diabetics |
| G6PD deficiency | Use with caution |
Contraindications: Pre-existing retinal/visual field changes, psoriasis, porphyria (standard doses), hypersensitivity to 4-aminoquinolines.
Quick Reference Summary
| Indication | Dose |
|---|---|
| SLE / RA (adult) | 200-400 mg/day (max 5 mg/kg/day) |
| SLE (child) | 3.1-5 mg/kg/day; max 310 mg/day |
| Malaria prophylaxis (adult) | 310 mg base weekly |
| Malaria prophylaxis (child) | 5 mg/kg base weekly |
| Malaria treatment (adult) | 620 → 310 → 310 → 310 mg base over 48 hr |
hydroxychloroquine dose for post viral infaction
HCQ is not a standard antiviral drug, but it has been used for post-viral inflammatory conditions (e.g., post-COVID arthritis/serositis, reactive arthritis, post-viral lupus flares) at the usual rheumatologic dose of 200-400 mg/day. Let me search the evidence more carefully.
Searching sources...
Finding Sources
Searching PubMed
hydroxychloroquine "post-viral" OR "long COVID" OR "post-COVID" syndrome treatment
Searching the Web
hydroxychloroquine post viral infection dose indication arthritis serositis evidence 2024
Reading File
Searching PubMed
hydroxychloroquine "reactive arthritis" OR "post-chikungunya" OR "post-infectious" arthritis treatment
Searching the Web
hydroxychloroquine post chikungunya post viral arthritis dose treatment guidelines
Reading Article
PMID: 36922870
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC10115449
Now I have solid, nuanced information. Here is the detailed answer:
Hydroxychloroquine Dose for Post-Viral Infection
Important context: HCQ has no established antiviral role for post-viral syndromes. Its use after viral infections is specifically for post-viral inflammatory/autoimmune manifestations - particularly persistent arthritis, arthralgia, and serositis triggered by the preceding viral infection.
Where HCQ Is Actually Used Post-Viral
1. Post-Chikungunya Arthritis (Most Common Use in India)
This is the most studied post-viral indication for HCQ in clinical practice.
| Aspect | Detail |
|---|---|
| Indication | Persistent polyarthritis lasting > 4-6 weeks after acute chikungunya fever |
| Dose | 200-400 mg/day (same as RA dosing) |
| Weight cap | ≤ 5 mg/kg/day actual body weight |
| Typical regimen | 200 mg twice daily or 400 mg once daily |
| Duration | Usually given for several months; response assessed at 12-24 weeks |
Evidence caveat: A 2023 systematic review (PMC10115449) noted that some RCT data show HCQ offers no significant therapeutic advantage over NSAIDs alone in acute chikungunya arthritis. However, for chronic persistent chikungunya arthritis (> 3 months), HCQ (sometimes combined with methotrexate) remains commonly used as first-line DMARD therapy, particularly in resource-limited settings.
2. Post-COVID Reactive Arthritis
Post-COVID reactive arthritis typically appears 22 ± 11 days after COVID-19 infection (PMID 36922870, Systematic Review 2023).
| Aspect | Detail |
|---|---|
| Indication | Persistent joint inflammation attributed to post-COVID immune activation |
| Dose | 200-400 mg/day (same rheumatologic dosing) |
| First-line | NSAIDs are first-line; HCQ added if persistent (> 4-6 weeks) |
| Evidence | Mainly case reports and case series; no dedicated RCTs for HCQ in post-COVID arthritis |
Management of post-COVID reactive arthritis is heterogeneous and mostly symptom-driven. Most cases resolve within weeks with NSAIDs alone.
3. Post-Viral Lupus Flare / SLE Triggered by Viral Infection
Viral infections (EBV, CMV, COVID-19, parvovirus B19) can trigger or unmask SLE.
| Aspect | Detail |
|---|---|
| Dose | 200-400 mg/day (standard SLE dosing, max 5 mg/kg/day) |
| Role | Background immunomodulator; reduce lupus activity and prevent future flares |
| Continue during pregnancy | Yes - reduces flare risk |
4. Post-Viral Sjogren's Syndrome Features / Serositis
| Dose | 200-400 mg/day - same principle as for SLE |
What HCQ Does NOT Work For Post-Viral
| Condition | Evidence |
|---|---|
| Long COVID fatigue / brain fog | No RCT evidence supporting HCQ; not recommended |
| COVID-19 treatment or post-exposure prophylaxis | Multiple large RCTs (RECOVERY, SOLIDARITY) showed no benefit; not recommended |
| Post-viral CFS/ME | No evidence |
Dosing Summary
| Post-Viral Scenario | HCQ Dose | Duration |
|---|---|---|
| Post-chikungunya arthritis (chronic) | 200-400 mg/day (≤ 5 mg/kg/day) | 3-6 months, reassess |
| Post-COVID reactive arthritis | 200-400 mg/day | Until remission; titrate to response |
| Post-viral SLE/serositis | 200-400 mg/day | Long-term |
| Post-viral fatigue / Long COVID | Not indicated | - |
Key Safety Reminder
- Maximum dose: ≤ 5 mg/kg/day of actual body weight regardless of indication
- Ophthalmology baseline exam within first year of starting; annual screening thereafter
- Avoid in: pre-existing retinal disease, G6PD deficiency, QT-prolonging drug combinations
(Goldman-Cecil Medicine; Firestein & Kelley's Rheumatology; PMID 36922870)
This is a shared conversation. Sign in to Orris to start your own chat.